TP53and breast cancer
Open Access
- 24 February 2003
- journal article
- review article
- Published by Hindawi Limited in Human Mutation
- Vol. 21 (3) , 292-300
- https://doi.org/10.1002/humu.10174
Abstract
The TP53 gene (p53) is found altered in breast carcinomas in approximately 20–40% of all cases depending on tumor size and stage of the disease. It seems to be an early event in breast tumorigenesis. Several polymorphisms in the TP53 gene have been detected and their possible roles in breast cancer risk and association to type of cancer developed are discussed. The different mutation spectra seen in geographical and ethnic populations may be used to identify environmental exposure contributing to breast cancer development. The role of TP53 mutation as a prognostic marker is reviewed as well as its role as a predictor for therapy response. All data available on TP53 mutation analyses of human breast carcinomas, as well data from transgenic animal studies and experimental cell studies, support an important role for TP53 in mammary carcinogenesis. Hum Mutat 21:292–300, 2003.Keywords
This publication has 48 references indexed in Scilit:
- The UMD-p53 database: New mutations and analysis toolsHuman Mutation, 2003
- A prospective trial of midwest breast cancer patients: Ap53 gene mutation is the most important predictor of adverse outcomeInternational Journal of Cancer, 2000
- Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancerBritish Journal of Cancer, 1998
- p53 gene mutation: software and databaseNucleic Acids Research, 1998
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapyNature Medicine, 1995
- Alterations of the TP53 Gene as a Potential Prognostic Marker in Breast CarcinomasDiagnostic Molecular Pathology, 1995
- TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domainsGenes, Chromosomes and Cancer, 1995
- P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessmentCancer, 1994
- Prognostic significance of TP53 alterations in breast carcinomaBritish Journal of Cancer, 1993